After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
ZYME belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Zymeworks BC Inc is $1.02B. A total of 0.56 million shares were traded on the day, compared to an average of 499.31K shares.
In the most recent transaction, EcoR1 Capital, LLC bought 121,681 shares of ZYME for 13.88 per share on Jan 16 ’25. After the transaction, the Director now owns 15,700,413 company shares. In a previous transaction on Jan 17 ’25, EcoR1 Capital, LLC bought 19,748 shares at 13.87 per share. ZYME shares that Director owns now total 15,720,161.
Among the insiders who bought shares, EcoR1 Capital, LLC acquired of 74,125 shares on Jan 13 ’25 at a per-share price of $13.39. This resulted in the Director holding 15,485,203 shares of ZYME after the transaction. In another insider transaction, EcoR1 Capital, LLC bought 54,500 shares at $13.56 per share on Jan 14 ’25. Company shares held by the Director now total 15,539,703.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, ZYME has a high of $17.70 and a low of $7.97.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ZYME’s latest balance sheet shows that the firm has $252.61M in Cash & Short Term Investments as of fiscal 2021. There were $32.33M in debt and $71.85M in liabilities at the time. Its Book Value Per Share was $5.23, while its Total Shareholder’s Equity was $249.09M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ZYME is Buy with a score of 4.50.
